Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28091851 | 0.85 | AKR1C3 (0.47) | ALDH1A1MAPT | |
| SCHEMBL10781545 | 0.84 | MAPT (0.44) | MAPT | |
| SCHEMBL28433779 | 0.84 | HTR6 (0.39) | CYP2D6KCNH2HTR6 | |
| SCHEMBL14775611 | 0.84 | HTR6 (0.37) | SLC6A2SLC6A4HTR6ALDH1A1 | |
| SCHEMBL27828787 | 0.84 | DRD2 (0.40) | SLC6A2SLC6A3SLC6A4KCNH2DRD2 | |
| SCHEMBL5821011 | 0.84 | MMP2 (0.33) | DRD2HTR2ADRD3 | |
| SCHEMBL3866888 | 0.84 | DRD2 (0.34) | DRD2DRD3HTR1A | |
| SCHEMBL4771959 | 0.84 | GLA (0.35) | DRD2DRD3 | |
| SCHEMBL16345364 | 0.83 | ENPP2 (0.40) | DRD2DRD3 | |
| SCHEMBL28285203 | 0.83 | CA12 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440132-B | Novel method for preparing oxygen heterocyclic compound by ionic liquid catalysis | 中国科学院化学研究所 | 2022-02-01 | — | — | CN | claimed |
| CN-111440132-A | Novel method for preparing oxygen heterocyclic compound by ionic liquid catalysis | 中国科学院化学研究所 | 2020-07-24 | — | — | CN | claimed |
| EP-0489085-B1 | RIGID-ROD POLYMERS | MISSISSIPPI POLYMER TECHNOLOGI (US) | 2005-12-07 | — | — | EP | claimed |
| CN-111440132-B | Novel method for preparing oxygen heterocyclic compound by ionic liquid catalysis | 中国科学院化学研究所 | 2022-02-01 | — | — | CN | disclosed |
| CN-111440132-A | Novel method for preparing oxygen heterocyclic compound by ionic liquid catalysis | 中国科学院化学研究所 | 2020-07-24 | — | — | CN | disclosed |
| CN-110015984-A | Substituted (E)-N '-(1- phenylethylene) benzoyl hydrazine analog as histone demethylase inhibitor | 犹他大学研究基金会 | 2019-07-16 | — | — | CN | disclosed |
| CN-105555784-B | Substituted (E) -N' - (1-phenylethylene) benzoyl hydrazine analogs as histone demethylase inhibitors | 犹他大学研究基金会 | 2019-03-15 | — | — | CN | disclosed |
| CN-105814035-B | Bruton's tyrosine kinase inhibitor | 豪夫迈·罗氏有限公司 | 2018-02-02 | — | — | CN | disclosed |
| US-20170334865-A1 | DDR2 INHIBITORS AND METHODS OF USING | WASHINGTON UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| WO-2016070024-A1 | DDR2 INHIBITORS AND METHODS OF USING | WASHINGTON UNIVERSITY (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334865-A1 | DDR2 INHIBITORS AND METHODS OF USING | DDR2, DDR1, DDRGK1 | SLC6A2 3942/4885SLC6A3 4070/4885SLC6A4 4609/4885 |
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | SLC6A2 4798/4885SLC6A3 4559/4885SLC6A4 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.